A 'Holy Grail' Sleep Apnea Pill Could Be On The Market Next Year

Key Concepts

• Obstructive Sleep Apnea (OSA): A condition where breathing repeatedly stops and starts during sleep.
• Apnea-Hypopnea Index (AHI): A measure used to indicate the severity of sleep apnea, quantifying the number of apneas (complete cessation of breathing) and hypopneas (shallow breathing) per hour of sleep.
• CPAP Machine: The current primary treatment for OSA, delivering continuous positive airway pressure to keep the airway open.
• Acne Med: A Cambridge, Massachusetts-based startup developing a pill-based treatment for OSA.
• Drug Combination: The potential treatment utilizes a combination of two existing drugs to stimulate the brainstem and prevent airway collapse.

A Potential Pill for Sleep Apnea: Development and Outlook

In November 2016, Harvard researcher Dr. Luigi Toranto Matamorro observed unexpectedly positive results while testing a drug combination on a patient with obstructive sleep apnea (OSA) at Brigham and Women's Hospital. The patient, typically exhibiting numerous breathing pauses during sleep, demonstrated normal breathing patterns during the trial. Dr. Toranto Monttomoro noted, “Usually this guy was full of apneas, and suddenly he was breathing well.” This observation sparked the development of a potential pill-based treatment for OSA, a condition affecting an estimated 80 million Americans.

The Science Behind the Medication

The medication developed by Acne Med, which acquired the rights from Harvard, functions by stimulating the brainstem. This stimulation prevents complete muscle relaxation in the throat during sleep, allowing for continued airflow while simultaneously permitting the brain to rest. This differs from current treatments like CPAP machines, which mechanically force air into the airway.

Clinical Trial Results & FDA Approval Pathway

Over the past eight years, Acne Med has refined the two-drug pill. Phase 3 clinical trials demonstrated significant improvements in patient breathing. Specifically, one study showed a 47% reduction in the apnea-hypopnea index (AHI) at 26 weeks for patients taking the drug, compared to a 7% reduction in the placebo group. Importantly, no serious adverse events were reported. The company is preparing to file for FDA approval, with a potential market launch anticipated in the first half of 2027.

Market Opportunity and Competitive Landscape

The current primary treatment for OSA, the CPAP machine, is often poorly tolerated by patients, leading to low adherence rates. Research indicates that only 6.5 million of the 23 million diagnosed individuals currently receive treatment. Acne Med’s Chief Commercial Officer, Graham Goodrich, highlights this issue stating, “We believe the majority of people who are diagnosed are not being treated.” This represents a substantial untapped market. While Eli Lilly’s Zeppound was recently FDA-approved for obese patients with OSA, it addresses the condition through weight loss, not a direct treatment of the airway obstruction. Acne Med believes a more accessible treatment option will expand the overall market.

Historical Context and Company Formation

Dr. Andrew Wellman, the Harvard sleep researcher overseeing the initial research, initially doubted the findings, stating, “I honestly didn't believe our findings were real.” However, the promising data prompted him to contact Dr. Larry Miller, a pulmonologist and entrepreneur. Dr. Miller, who had previously considered abandoning OSA drug development, was convinced by the results, saying, “Before this one, I thought I was done. But when Andrew called me about the data, I thought, this is too good. I have to do it.” In 2017, Dr. Miller launched Apne (now Acne Med) with Dr. Toranto Monttomoro as co-founder and Chief Scientific Officer. The company has since raised $260 million in investment, achieving a $400 million valuation.

Future Implications and Vision

Dr. Miller envisions a future where OSA is managed similarly to other chronic conditions like asthma or high blood pressure, offering physicians a range of treatment options tailored to individual patient needs. He states, “It will be like asthma or high blood pressure. As a physician, you try to choose the best option for the patient. That hasn't been possible until now.” He anticipates significant demand for the medication, predicting usage “in the millions.”

Conclusion

The development of a pill-based treatment for obstructive sleep apnea by Acne Med represents a potentially transformative advancement in the field. Backed by promising clinical trial data and a significant market opportunity, this medication could offer a more accessible and tolerable treatment option for the millions of individuals currently suffering from this often-underdiagnosed and undertreated condition. The potential impact extends beyond improved patient quality of life, potentially mitigating the increased risk of cardiovascular disease, stroke, and neurodegenerative disorders associated with untreated OSA.